



Phenobiome Announces Breakthrough Clinical Trial Validating Predictive Microbiome Modulation

February 2025

Phenobiome, a leader in precision microbiome technologies, today announced the successful completion of a clinical trial demonstrating its advanced *in silico* phenotype platform's ability to drive real-world improvements in gut health. The study, conducted over 60 days with 30 participants, evaluated the impact of personalized prebiotic and micronutrient formulations on gut microbial composition and metabolic function.

Transforming Predictions Into Outcomes

Leveraging cutting-edge 16S sequencing, Phenobiome's approach uses proprietary algorithms to predict how specific nutritional interventions will modulate the gut microbiome. In this trial, four formulation strategies were employed: a prebiotic blend designed to boost carbohydrate-utilizing microbes, and three different vitamin-rich blends aimed at modulating vitamin-utilizing species. The results were compelling, participants receiving the prebiotic formulation exhibited a significant increase in the fractional representation of carbohydrate-utilizing microbes, while those on the vitamin formulations experienced a markedly increased representation of vitamin-utilizing microbes. These outcomes perfectly mirrored the *in-silico* predictions, providing robust proof of concept.

A Smart Approach to Personalized Gut Health

"Our clinical trial clearly demonstrates that our predictive models translate into meaningful, measurable changes in gut microbiota," said Didier Perez, CEO of Phenobiome. *"This breakthrough validates our ability to create targeted nutritional interventions that not only address individual gut health challenges but also pave the way for personalized nutrition and precision healthcare solutions on a broader scale."* Adding further validation to our approach, Prof. Andrei Osterman, co-founder and lead scientist, remarked, *"It is incredibly rewarding to receive confirmation that the Science we have dedicated so much time and energy to is effective and provides accurate predictions of physiological outcomes!"*

Broad Implications and Market Potential

The success of this trial underscores Phenobiome's potential to revolutionize how we approach health through the microbiome lens. By accurately predicting microbial responses and delivering customized formulations, the technology is poised to address a wide range of health challenges, including metabolic disorders, immune function, gut-brain, and women's health. This scalable, science-backed platform offers significant opportunities for further clinical expansion, commercialization, and strategic partnerships in a rapidly growing market.

About Phenobiome

Phenobiome is at the forefront of precision microbiome modulation, harnessing advanced computational modeling and personalized nutritional formulations to transform health. With a focus on delivering scalable, evidence-based solutions, Phenobiome is committed to improving health outcomes through tailored interventions that address individual microbiome variability.

For additional information, please contact: Didier G. Perez, CEO For inquiries, please email us at didier@phenobiome.com.